TNFRSF10B KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Form
- Liquid
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1
Alternative names
Apoptosis inducing protein TRICK2A/2B, Apoptosis inducing receptor TRAIL R2, CD262, CD262 antigen, Cytotoxic TRAIL receptor 2, DR5, Death domain containing receptor for TRAIL/Apo 2L, Death receptor 5, Fas like protein, KILLER, KILLER/DR5, OTTHUMP00000123492, OTTHUMP00000123493, TNF-related apoptosis-inducing ligand receptor 2, TNFRSF10B, TR10B_HUMAN, TRAIL receptor 2, TRAIL-R2, TRICK2, TRICK2A, TRICK2B, TRICKB, Tumor necrosis factor receptor like protein ZTNFR9, Tumor necrosis factor receptor superfamily member 10B, ZTNFR9, p53 regulated DNA damage inducible cell death receptor(killer)
Recommended products
TNFRSF10B KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Form
- Liquid
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- TNFRSF10B
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing, Western blot
- Zygosity
- Homozygous
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.- Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Culture medium
- DMEM (High Glucose) + 10% FBS
- Cryopreservation medium
- Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage conditions
- -196°C
- Appropriate long-term storage conditions
- -196°C
Notes
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
DR5 also known as Death Receptor 5 TRAIL-R2 or TNFRSF10B is a protein critical in apoptosis. It is a transmembrane receptor with a mass of approximately 54 kDa. Researchers find it expressed mostly in tissues such as lung colon and prostate. DR5 functions by binding to its ligand TRAIL triggering the extrinsic apoptotic pathway. Through this mechanism DR5 initiates a cascade of caspase activation that leads to cell death.
- Biological function summary
DR5 plays a significant role in the regulation of apoptosis particularly in cancer cells. It is a component of the TRAIL receptor complex which includes several other death receptors like DR4. This complex formation allows DR5 to mediate apoptotic signals more efficiently. By controlling apoptosis DR5 helps maintain tissue homeostasis and prevents abnormal cell proliferation.
- Pathways
DR5 is an important part of the TRAIL signaling pathway and the extrinsic apoptosis pathway. It connects with proteins like FADD and Caspase-8 essential in the apoptotic signaling cascade. By interacting with these proteins DR5 drives the progression of the apoptotic signal ensuring the removal of dysfunctional cells. Such pathways are vital for restraining tumor development and progression.
- Associated diseases and disorders
DR5 exhibits significant relevance to cancer and autoimmune diseases. Its ability to induce apoptosis through the TRAIL pathway keeps oncogenic transformations in check. In cancer DR5 often interfaces with other proteins like Bcl-2 which are involved in cell survival. Furthermore defects or aberrant expressions in DR5 have associations with autoimmune disorders where excessive cell death or survival contributes to disease pathology. DR5's role in these conditions makes it a promising target in therapeutic strategies.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Sanger Sequencing - Human TNFRSF10B (DR5) knockout HeLa cell line (ab264922)
Homozygous: Insertion of the selection cassette in exon 1.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com